**Financial Highlights:** Q1FY26 operating income for Zim Laboratories was ₹71.8 Cr, down 12.3% YoY.

EBITDA declined 36.7% to ₹5.7 Cr, with margins at 7.9%. The company reported a net loss of ₹1.9 Cr, impacted by lower revenue and higher costs.

Dossier outlicensing fees contributed ₹4.5 Cr. **Strategic Initiatives & Growth Drivers:** Zim invested ₹7.9 Cr in R&D, including ₹1.9 Cr for BE studies and regulatory filings, underscoring its focus on pipeline advancement.

A new BD team with regional heads was onboarded for Africa, CIS, LatAm, MENA, and SE Asia to drive market expansion. **Business Developments:** The company filed 1 NIP in EU and 14 ODS/NIPs in other markets, securing 5 Marketing Authorizations, including two for oral films via its Australian subsidiary.

India business grew 30.2% to ₹10.0 Cr, partially offsetting export decline due to geopolitical issues. **Market Position & Competitive Advantage:** Pharma business remains the core, contributing 78% of revenue.

The 90-member R&D team and an extensive product pipeline, including 8 NIPs filed in EU, highlight the company's innovation-driven competitive advantage in specialized formulations. **Investor Implications:** While Q1 faced headwinds from geopolitical instability impacting exports, significant R&D investment and a robust product pipeline suggest positive long-term growth potential.

Investors should monitor execution risk related to market recovery and new product commercialization.